Nexavar Survival Study In Asia-Pacific Patients With Liver Cancer Halted Early
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III study found that sorafenib significantly improved overall survival and progression-free survival in patients with hepatocellular carcinoma.
You may also be interested in...
Bayer/Onyx Submit Nexavar sNDA For Liver Cancer
Filing is based on halted Phase III trial showing overall survival of 44 percent in patients with hepatocellular carcinoma treated with sorafenib.
Bayer/Onyx’ Nexavar Approved For Kidney Cancer
FDA’s full approval of the oncologic indicates sorafenib for broad use by all patients with advanced renal cell carcinoma.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.